Back to Search
Start Over
Exceptional response to lurbinectedin and irinotecan in BRCA -mutated platinum-resistant ovarian cancer patient: a case report.
- Source :
-
Therapeutic advances in chronic disease [Ther Adv Chronic Dis] 2022 Jan 13; Vol. 13, pp. 20406223211063023. Date of Electronic Publication: 2022 Jan 13 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Lurbinectedin is responsible for DNA recognition and binding, producing double-strand DNA (dsDNA) breaks thus resulting in apoptosis. Sensitivity to lurbinectedin is linked to the nucleotide excision repair (NER) system. Furthermore, irinotecan, a topoisomerase I inhibitor, provokes dsDNA breaks that could be reinforced abrogating the NER system using lurbinectedin. BRCA -mutated patients, already treated with platinum-derived drugs, who suffered DNA damage, cannot repair the breaks due to lurbinectedin interaction, whereas irinotecan provokes a dsDNA break that promotes synthetic lethality. This article describes an exceptional response to lurbinectedin alone followed by the association with irinotecan in a BRCA -mutated platinum-resistant ovarian cancer patient. A 44-year-old BRCA 1-mutated ovarian cancer patient was treated in sixth line with lurbinectedin and irinotecan with a time to further progression (TTFP) equal to 8 months. In our case, the association with irinotecan overcame the resistance to lurbinectedin alone. In conclusion, lurbinectedin and irinotecan demonstrated a promising response in platinum-resistant patients. However, further studies should be conducted to validate our findings and future trials will be important to further define the clinical utility of lurbinectedin.<br />Competing Interests: Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: LC: honoraria: AstraZeneca, MSD, Pfizer; Consulting or Advisory Role: Pfizer, Novartis, GSK, Clovis. No other potential conflicts of interest were reported.<br /> (© The Author(s), 2022.)
Details
- Language :
- English
- ISSN :
- 2040-6223
- Volume :
- 13
- Database :
- MEDLINE
- Journal :
- Therapeutic advances in chronic disease
- Publication Type :
- Report
- Accession number :
- 35070248
- Full Text :
- https://doi.org/10.1177/20406223211063023